Brainsway Ltd
TASE:BWAY
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
937.1
2 026
|
| Price Target |
|
We'll email you a reminder when the closing price reaches ILS.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Brainsway Ltd
Gross Profit
Brainsway Ltd
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Brainsway Ltd
TASE:BWAY
|
Gross Profit
$23.5m
|
CAGR 3-Years
11%
|
CAGR 5-Years
13%
|
CAGR 10-Years
37%
|
|
|
Nano-X Imaging Ltd
NASDAQ:NNOX
|
Gross Profit
-$6.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Inmode Ltd
NASDAQ:INMD
|
Gross Profit
$345.9m
|
CAGR 3-Years
8%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Sisram Medical Ltd
HKEX:1696
|
Gross Profit
$219.5m
|
CAGR 3-Years
22%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sofwave Medical Ltd
TASE:SOFW
|
Gross Profit
$37.5m
|
CAGR 3-Years
142%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
E
|
Epitomee Medical Ltd
TASE:EPIT
|
Gross Profit
$9.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Brainsway Ltd
Glance View
Brainsway Ltd. is a commercial stage medical device company, which focuses on the development and sale of non-invasive neuromodulation products using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The firm primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.
See Also
What is Brainsway Ltd's Gross Profit?
Gross Profit
23.5m
USD
Based on the financial report for Dec 31, 2023, Brainsway Ltd's Gross Profit amounts to 23.5m USD.
What is Brainsway Ltd's Gross Profit growth rate?
Gross Profit CAGR 10Y
37%
Over the last year, the Gross Profit growth was 17%. The average annual Gross Profit growth rates for Brainsway Ltd have been 11% over the past three years , 13% over the past five years , and 37% over the past ten years .
You don't have any saved screeners yet
